APELLIS PHARMS
PharmaAPELLIS PHARMS is a pharmaceutical company focused on Ophthalmology. Key products include EMPAVELI.
FDA Novel Drug Designations
(2021)See 1 novel approval →
APELLIS PHARMS at a Glance
- Growing R&D activity with 4 trials in last 2 years
- Fast trial execution (34 months median completion)
APELLIS PHARMS's Key Drugs
APELLIS PHARMS's core commercial portfolio centers on EMPAVELI, SYFOVRE, spanning Ophthalmology — its most strategically important drugs approved in the last 15 years.
APELLIS PHARMS's Recent FDA Approvals
New NDA/BLA approvals for APELLIS PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
APELLIS PHARMS's Therapeutic Areas
APELLIS PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Ophthalmology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
APELLIS PHARMS's Top Competitors
APELLIS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and OTSUKA ICU MEDCL. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
APELLIS PHARMS Pipeline Snapshot
Active clinical trials for APELLIS PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
4 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • EMPAVELI leads revenue
- • 2 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/10 completed
- • Speed: 34 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges